Eric Sievers - 01 Oct 2021 Form 4 Insider Report for BioAtla, Inc. (BCAB)

Reporting relationship: Chief Medical Officer
Issuer ticker: BCAB
Reported as of: 01 Oct 2021
Net transaction value: -$17,993
SEC form: 4
Accepted by SEC: 07 Oct 2021, 18:08:21 UTC
Prior SEC filing: 30 Aug 2021
Next SEC filing: 30 Nov 2021
Source filing: View source filing
Reporting owner signature: /s/ Chris Vasquez, as Attorney-in-Fact for Eric Sievers

Key filing fact

Eric Sievers filed Form 4 for BioAtla, Inc. (BCAB) on 07 Oct 2021.

Key facts

This page summarizes Eric Sievers's Form 4 filing for BioAtla, Inc. (BCAB).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 07 Oct 2021, 18:08.

Change

Previous filing in this sequence was filed on 30 Aug 2021.
Current net transaction value: -$17,993.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCAB transaction

Common Stock

Sale

Transaction value: $17,993
Shares: -592
Change %: -0.63%
Price: $30.39^*
Shares after: 93,174
Date: 01 Oct 2021
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs.

Footnote F2

The range of prices for the shares of Common Stock is from $30.20 to $30.47. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price.